Less than a month after going public, Neon Therapeutics has hired its first-ever general counsel.

Jolie Siegel will lead the legal, intellectual property, compliance and corporate governance functions for the Cambridge, Massachusetts-based company, which develops clinical-stage cancer drugs. She most recently was senior vice president, deputy GC and assistant secretary at financial technology provider Intralinks Inc.

Siegel could not be immediately reached for comment, but in a company statement announcing her appointment, she referenced the potential of Neon's work to increase the efficacy of immunotherapy and improve patient outcomes.

“I am thrilled to join Neon at this important juncture in the company's development,” she said.

Neon is focused on transforming cancer treatment by directing the body's immune system toward so-called neoantigens, or markers that are unique to each individual tumor. Given the success of truly personalized medicine in oncology, the company was one of the more highly anticipated IPOs that came out in the field this year, according to news reports.

“Jolie will be an invaluable resource as we advance the clinical trials of our personalized and precision therapeutics,” Neon president and CEO Hugh O'Dowd said in a statement. “We're delighted to welcome her to the Neon team.”

Prior to joining Intralinks in February 2013, Siegel was a partner at Boston-based Choate Hall & Stewart, where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high-growth companies.

A graduate of the University of Pennsylvania Law School, Siegel began her legal career as an attorney at the now-dissolved Boston-based firm Testa, Hurwitz & Thibeault, where she was a member of the business practice group, according to her LinkedIn profile.